Google’s ALS drug fails phase 3 trial

Fosigotifator, an amyotrophic lateral sclerosis drug developed by Calico Life Sciences, a biotech company backed by Google’s parent company Alphabet, failed to meet its primary endpoint, according to topline results from the Healey ALS platform trial. 

Advertisement

Fosigotifator did not demonstrate a significant effect on disease progression, combining function and mortality measures, in either the primary or the exploratory high-dose groups. 

Secondary endpoints, including the revised ALS functioning rating scale, respiratory function and health-related quality of life also showed no statistically significant improvement compared to the placebo. However, a slight signal was observed in muscle strength, with slower deterioration in both upper and lower extremities for patients in the high-dose group. 

Despite the negative trial outcome for ALS, fosigotifator is still being studied for other conditions, including vanishing white matter disease and major depressive disorder. 

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.